NCT00224263

Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 360 (planned)
• Sponsor: Xuanwu Hospital, Beijing · Academic / Other
• Sex: All
• Age: 30 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Lingzhi (Ganoderma), a widely used traditional Chinese Medicine is effective and safe in the treatment of Parkinson's disease when combined use with L-dopa.

Detailed description

This study is to focus on the effects of Lingzhi on non-motor symptoms of Parkinson's diseases as the primary outcome and on delaying the disease progression using the delay start design as the secondary outcome measurement. Two dosage groups and one placebo control group with total 360 subjects will be recruited. The treatment is one year.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	Lingzhi (Ganoderma)

Timeline

• Start date: 2005-09-01
• Completion: 2008-02-01
• First posted: 2005-09-22
• Last updated: 2011-08-16

Locations

1 site across 1 country: China